# Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

> **NCT00640328** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 38 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ofatumumab 100
- **DRUG:** Ofatumumab 300
- **DRUG:** Ofatumumab 700
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00640328
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-05
- **Final completion:** 2011-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640328, "Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00640328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*